Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
EARLY_PHASE1
58 participants
INTERVENTIONAL
2021-02-15
2022-02-09
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
The COVID-19 VaccinE Response and Co-Administration in Rheumatology Patients (COVER-CoAd)
NCT05543642
COVID-19 Vaccination in Patients With Rheumatic Diseases
NCT04845997
COvid-19 Vaccine Booster in Immunocompromised Rheumatic Diseases
NCT05236491
COVID-19 VaccinE Response in Rheumatology Patients
NCT05080218
COVID-19 Infection in Vulnerable Patients With Inflammatory Rheumatic Diseases
NCT04335747
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
HEALTH_SERVICES_RESEARCH
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
mRNA COVID19 vaccines
mRNA-based COVID19 vaccines
mRNA COVD19 vaccine
Subjects will receive two doses of mRNA based COVID19 vaccines.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
mRNA COVD19 vaccine
Subjects will receive two doses of mRNA based COVID19 vaccines.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Systemic lupus erythematosus;
* Sjogren syndrome;
* Inflammatory myositis;
* Psoriatic arthritis;
* Osteoarthritis;
* Gout;
* Ankylosing spondylitis;
* IBD-related arthritis.
Exclusion Criteria
* Pregnancy
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Mayo Clinic
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Hu Zeng
Principal Investigator
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Hu Zeng, PhD
Role: PRINCIPAL_INVESTIGATOR
Mayo Clinic
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Mayo Clinic in Rochester
Rochester, Minnesota, United States
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
Mayo Clinic Clinical Trials
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
21-000501
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.